Abstract: The present invention relates to novel cycloalkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP kinases, preferably p38 kinase. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.
Type:
Grant
Filed:
August 27, 2003
Date of Patent:
February 28, 2006
Assignee:
Pfizer Inc.
Inventors:
Mark A. Dombroski, Michael A. Letavic, Kim F. McClure
Abstract: The invention provides compounds of Formula I: wherein Azabicyclo is W is a six-membered heterocyclic ring system having 1–2 nitrogen atoms or a 10-membered bicyclic-six-six-fused-ring system having up to two nitrogen atoms within either or both rings, provided that no nitrogen is at a bridge of the bicyclic-six-six-fused-ring system, and further having 1–2 substitutents independently selected from R3. These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals to treat diseases or conditions in which ?7 is known to be involved.
Type:
Grant
Filed:
February 14, 2003
Date of Patent:
February 21, 2006
Assignee:
Pfizer Inc.
Inventors:
Eric Jon Jacobsen, Jason K. Myers, Daniel Patrick Walker, Donn G. Wishka, Steven Charles Reitz, David W. Piotrowski, Brad A. Acker, Vincent E. Groppi, Jr.
Abstract: Nucleic acid molecules encoding at least part of a Type I polyketide synthase, and having a polylinker with multiple restriction enzyme sites in place of one or more PKS genes encoding enzymes associated with reduction, optionally further including nucleic acid incorporated into the polylinker, the further nucleic acid encoding one or more reductive enzymes; plasmids incorporating such nucleic acids; host cells transfected with such plasmids; methods relating thereto.
Type:
Grant
Filed:
July 6, 1999
Date of Patent:
February 21, 2006
Assignees:
Biotica Technology Limited, Pfizer, Inc.
Inventors:
Johannes Kellenberger, Peter Francis Leadlay, James Staunton, Kim Jonelle Stutzman-Engwall, Hamish Alastair Irvine McArthur
Abstract: Prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits containing such prostaglandin agonists. The prostaglandin agonists are useful for the treatment of bone disorders including osteoporosis.
Type:
Grant
Filed:
August 29, 2003
Date of Patent:
February 14, 2006
Assignee:
Pfizer Inc.
Inventors:
Kimberly O. Cameron, Hua Z. Ke, Bruce A. Lefker, Robert L. Rosati, David D. Thompson
Abstract: Methods of selectively removing counterions from compounds are disclosed. Compounds derived from the methods, such as the compound S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine zwitterion with between zero and up to 2 molar equivalents of hydrochloride are also disclosed.
Abstract: Compounds of Formula (IC) that act as 5-HT receptor ligands and their uses in the treatment of diseases linked to the activation of 5-HT2 receptors in animals are described herein .
Type:
Grant
Filed:
September 16, 2004
Date of Patent:
February 7, 2006
Assignee:
Pfizer Inc.
Inventors:
Phoebe Chiang, William A. Novomisle, Willard M. Welch, Jr.
Abstract: The present invention provides attenuated live cultures of the pathogenic protozoan parasite, Neospora, and live vaccines against neosporosis prepared therefrom which are useful in the prevention of clinical disease and abortion in mammals.
Type:
Grant
Filed:
September 24, 2003
Date of Patent:
February 7, 2006
Assignee:
Pfizer Inc
Inventors:
David A Brake, Byron L Blagburn, David S Lindsay
Abstract: The invention is a process to hydrogenate an aryl-substituted pyridine, such as 2-phenyl-3-aminopyridine, without over-reducing the aryl ring using a specific Pt/C catalyst.
Type:
Grant
Filed:
January 5, 2004
Date of Patent:
February 7, 2006
Assignee:
Pfizer INC
Inventors:
Timothy James Norman Watson, Michael Girard Vetelino
Abstract: Corticotropin-releasing factor (CRF) antagonists having the formula wherein the dashed lines, A, B, D E, F, Z, G, R3, and R5 having the definitions set forth in the specification pharmaceutical compositions containing them.
Abstract: Polynucleotide and polypeptide sequences are described. The polypeptide sequences comprise one or more of: (a) a polypeptide having the deduced amino acid sequence translated from the polynucleotide sequence in SEQ ID NO: 1 or SEQ ID NO: 5 and variants, fragments, homologues, analogues and derivatives thereof; (b) a polypeptide of SEQ ID NO: 2 and variants, fragments, homologues, analogues and derivatives thereof; (c) a polypeptide encoded by the cDNA of NCIMB 41110 and variants, fragments, homologues, analogues and derivatives thereof; or (d) a polypeptide which has at least 78% identity to (i) the polypeptide encoded by the polynucleotide of SEQ ID NO: 1 or SEQ ID NO: 5, (ii) the polypeptide of SEQ ID NO: 2, or (iii) the polypeptide encoded by the cDNA of NCIMB 41110. Such polypeptide sequences are, inter alia, useful in the prophylaxis and/or treatment of sexual dysfunction, in particular male erectile dysfunction (MED) or female sexual dysfunction (FSD), preferably female sexual arousal disorder (FSAD).
Type:
Grant
Filed:
September 7, 2001
Date of Patent:
January 31, 2006
Assignee:
Pfizer Inc.
Inventors:
Neil Benson, Helen Frances Boyd, Leonard Gabriel Contillo, Ian Dennis Harrow, Stephen Charles Phillips, David Harlan Singleton, Peter Stacey, Roderick Thomas Walsh, Christopher Peter Wayman
Abstract: Substituted aryl 1,4-pyrazine derivatives of formula I as defined herein and their use in treating anxiety disorders, depression and stress related disorders are disclosed.
Type:
Grant
Filed:
November 15, 2002
Date of Patent:
January 31, 2006
Assignee:
Pfizer Inc
Inventors:
Patrick R. Verhoest, Robert Louis Hoffman, Jeffrey W. Corbett, Michael Dalton Ennis, Kristine E. Frank, Jian-Min Fu
Abstract: The present invention provides compounds of formula (I) the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers, and prodrugs; wherein R1, R2, Ra, Rb, X, and Z are as defined herein; pharmaceutical compositions thereof; and uses thereof.
Type:
Grant
Filed:
April 15, 2004
Date of Patent:
January 31, 2006
Assignee:
Pfizer Inc.
Inventors:
Donald L. Bussolotti, Ronald B. Gammill
Abstract: The present invention provides compounds of formula (I) the prodrugs thereof, and the pharmaceutically acceptable salts of the compounds and prodrugs, wherein R?, R?, R??, and Z are as defined herein; pharmaceutical compositions thereof; and uses thereof in treating diabetes, insulin resistance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis, and tissue ischemia.
Type:
Grant
Filed:
November 6, 2003
Date of Patent:
January 31, 2006
Assignee:
Pfizer, Inc.
Inventors:
Donald L. Bussolotti, Ronald B. Gammill, Jana Polivkova
Abstract: The present invention relates to a method of treating a bacterial respiratory or acute otitis media infections in humans by administering a single dose of azithromycin wherein the dose is about 40 mg/kg body weight or greater.
Abstract: PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans.
Abstract: A vaccine for in ovo vaccination against avian coccidiosis produced by a method including obtaining the coccidial oocysts from a fecal suspension, homogenizing the fecal suspension, separating the oocysts from the fecal debris by either salt flotation using sodium sulfate or gas flotation using air, sporulating the oocysts using hydrogen peroxide and air sparging, bleaching the sporulated oocysts, washing the bleached oocysts, concentrating the sterile washed oocysts and combining the concentrates of various species of coccidial oocysts, and producing a vaccine. The method in whole or in part can be applied to other kinds of encysted protozoa to produce vaccines for various types of animals.
Type:
Grant
Filed:
February 25, 2000
Date of Patent:
January 10, 2006
Assignee:
Pfizer, Inc.
Inventors:
Harold N. Conkle, Joseph E. Schultz, Scott J. Blonigen, Fred H. Weber, David R. Kilanowski, Bruce Monzyk, Timothy M. Werner, Chad M. Cucksey, Hamish A. I. McArthur, Ted L. Tewksbury
Abstract: The present invention is related to an oral dosage form comprising an effective amount of an alkalizing agent and an azithromycin multiparticulate wherein said multiparticulate comprises azithromycin, a glyceride which comprises glyceryl monobehenate, glyceryl dibehenate, glyceryl tribehenate, or a mixture thereof and a poloxamer. Typically, the oral dosage form includes any suitable oral dosing means such as a powder for oral suspension, a unit dose packet or sachet, a tablet or a capsule.
Type:
Grant
Filed:
January 23, 2004
Date of Patent:
January 10, 2006
Assignee:
Pfizer Inc.
Inventors:
Timothy A. Hagen, Julian B. Lo, Avinash G. Thombre, Scott M. Herbig, Leah Elizabeth Appel, Marshall David Crew, Dwayne Thomas Friesen, David Keith Lyon, Scott Baldwin McCray, James Blair West
Abstract: The present invention provides compositions and methods for the use of antigenic peptides derived from the Fc portion of the epsilon heavy chain of IgE molecules from two unrelated species as vaccines for the treatment and prevention of IgE-mediated allergic disorders. In particular, the invention provides compositions for the treatment and prevention of IgE-mediated allergic disorders comprising an immunogenic amount of one or more antigenic peptides.
Abstract: Compounds which have utility in the treatment of conditions associated with altered mitochondrial function. The compounds have the following structure (I): including stereoisomers, prodrugs, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5 and R6 are as defined herein. Pharmaceutical compositions containing a compound of structure (I), as well as methods relating to the use thereof, are also disclosed.
Abstract: Isolated polynucleotide molecules contain a nucleotide sequence that encodes a L. intracellularis HtrA, PonA, HypC, LysS, YcfW, ABC1, or Omp100 protein, a substantial portion of the sequences, or a homologous sequence. Related polypeptides, immunogenic compositions and assays are described.